Director & 10% Owner Akkaraju Srinivas Reports $5M Stock Purchase

summarizeSummary

Director and 10% owner Akkaraju Srinivas, through Samsara Opportunity Fund, L.P., reported a significant $5 million open market purchase of Kalaris Therapeutics common stock, signaling strong insider confidence.

check_boxKey Events

• Substantial Insider Investment

  Director and 10% owner Akkaraju Srinivas, through Samsara Opportunity Fund, L.P., acquired $5,000,006 worth of Kalaris Therapeutics common stock.

• Purchase at Premium

  The shares were purchased at $10.42 per share on December 18, 2025, which is above the current market price of $8.265.

• Increased Indirect Holdings

  This transaction significantly increased the reporting person's indirect beneficial ownership to 1,979,847 shares.

• Amended Disclosure

  The filing serves as an amendment to a prior Form 4 filed on December 22, 2025, providing updated details on the December 18, 2025, purchase.

auto_awesomeAnalysis

This Form 4 filing reveals a substantial $5,000,006 open market purchase of Kalaris Therapeutics common stock by Director and 10% owner Akkaraju Srinivas, executed indirectly through Samsara Opportunity Fund, L.P. This significant investment, made at a price of $10.42 per share compared to the current stock price of $8.265, demonstrates strong conviction from a key insider despite the shares being acquired at a premium to today's market. The transaction, which occurred on December 18, 2025, and is reported as an amendment to a prior filing, represents a material vote of confidence in the company's future. This purchase likely contributes to the updated ownership information expected in the concurrently filed Schedule 13D/A. Investors should consider this a highly positive signal, indicating that a major stakeholder sees significant value in the company.